Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194863 | 0.89 | MAPT (0.41) | MAPK1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL9700761 | 0.86 | TSHR (0.49) | MAPK1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL2262385 | 0.85 | MAPT (0.48) | MAPK1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL633527 | 0.84 | TDP1 (0.44) | MAPK1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL1803434 | 0.80 | ALDH1A1 (0.47) | MAPK1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL2928829 | 0.78 | MAPK1 (0.53) | MAPK1TSHRMAPTLMNASMN1; SMN2 | |
| SCHEMBL21577681 | 0.78 | MAPT (0.40) | MAPK1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL30194794 | 0.76 | MAPT (0.41) | MAPK1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL11200193 | 0.75 | ALDH1A1 (0.44) | MAPK1TSHRMAPTLMNAKMT2A | |
| SCHEMBL13176425 | 0.73 | MAPK1 (0.47) | MAPK1TSHRMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | PFIZER LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| WO-2008050207-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANABOLIC AGENTS FOR LIVESTOCK ANIMALS | PFIZER LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | MAPK1 1646/4885TSHR 783/4885MAPT 2885/4885 |
| US-20080267942-A1 | BENZAZEPIN-2(1H)-ONE DERIVATIVES | ADRB2, ADRB1, ADRA2C | MAPK1 2354/4885TSHR 421/4885MAPT 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.